Clinical Trials
3 trialsNCT02613598 2021-12-20
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01965119 2018-11-01
JAK2
Samsung Medical Center
Phase 2 Completed
NCT01877005 2018-08-22
HIJAK
The Lymphoma Academic Research Organisation
Phase 2 Completed